UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study

Therapeutic advances in neurological disorders, 2024-11, Vol.17

2024

Volltextzugriff (PDF)

Investigation of Adaptation to Successive Postural Perturbations in Patients with Multiple Sclerosis

Türk nöroloji dergisi, 2020-03, Vol.26 (1), p.24-29

2020

Volltextzugriff (PDF)

Hidden Markov Model and multifractal method-based predictive quantization complexity models vis-á-vis the differential prognosis and differentiation of Multiple Sclerosis’ subgroups

Knowledge-based systems, 2022-06, Vol.246, p.108694, Article 108694

2022

Volltextzugriff (PDF)

Investigating the Side Effects of Treatments Among Different Age and Gender Groups of Multiple Sclerosis Patients (P2-6.015)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Real World Ocrelizumab Experience of a Tertiary Center in Turkey (4528)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

The Role of C3 and C4 Complement Levels in the Differential Diagnosis of Central Nervous System Demyelinating Diseases (P14-3.016)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Faible activité de la maladie après un traitement de 4 ans par ocrelizumab (OCR) chez des patients naïfs de traitement atteints de sclérose en plaques récurrente-rémittente (SEP-RR) à un stade précoce ; données de l’étude de phase IIIb ensemble

Revue neurologique, 2024-04, Vol.180, p.S146-S147

2024

Volltextzugriff (PDF)

Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-naive Patients with High-activity, Early-stage Relapsing-remitting Multiple Sclerosis in the ENSEMBLE Study (P10-6.007)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Faible activité de la maladie chez des patients naïfs de traitement, atteints de sclérose en plaques récurrente-rémittente (SEP-RR) précoce, ayant reçu ocrélizumab (OCR) pendant 2 ans dans l’étude de phase IIIb ENSEMBLE

Revue neurologique, 2023-04, Vol.179, p.S168-S168

2023

Volltextzugriff (PDF)

Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study (S46.004)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study (P7-3.003)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Investigation of Novel Variants in Familial Multiple Sclerosis Through Family-based Association Tests and Segregation Analyses (S17.007)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-β1 and fingolimod therapy

Journal of neuroimmunology, 2020-10, Vol.347, p.577353, Article 577353

2020

Volltextzugriff (PDF)

Erratum: Evaluating Treatment Decision for Multiple Sclerosis: Real Life and Patient Experiences

Noro-Psikiyatri Arsivi, 2019-03, Vol.56 (1), p.82-82

2019

Volltextzugriff (PDF)

Evaluating Treatment Decision for Multiple Sclerosis: Real Life and Patient Experiences

Noro-Psikiyatri Arsivi, 2018, Vol.55 (Suppl 1), p.S10-S14

2018

Volltextzugriff (PDF)

Corrigendum to Myelin Oligodendrocyte Glycoprotein Antibody Associated Central Nervous System Demyelinating Disease: A Tertiary Center Experience From Turkey [Multiple Sclerosis and Related Disorders 44 (2020) 102376]

Multiple sclerosis and related disorders, 2021-02, Vol.48, p.102581-102581, Article 102581

2021

Volltextzugriff (PDF)

Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course

Noro-Psikiyatri Arsivi, 2019-03, Vol.56 (1), p.23-26

2019

Volltextzugriff (PDF)

Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course

Noro-Psikiyatri Arsivi, 2019-03, Vol.56 (1), p.23-26

2019

Volltextzugriff (PDF)

Corrigendum to "Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment" Multiple Sclerosis and Related Disorders, Volume 79, November 2023, 104949

Multiple sclerosis and related disorders, 2024-10, Vol.92, p.105917

2024

Volltextzugriff (PDF)

Let’s raise the awareness of MS specialists concerning the frequency and impact of RLS in MS and consequently the life quality of patients with MS: Striking results of the ‘RELOMS-T’ Study (P1.424)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Optic Neuritis Presenting With Altitudinal Visual Field Defect in a Neuromyelitis Optica Patient

Journal of neurology research, 2017, Vol.7 (6), p.112-114

2017

Volltextzugriff (PDF)

Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis (2901)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Association of Latitude and Exposure to Ultraviolet B Radiation with Severity of Multiple Sclerosis (2554)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(68)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study

Investigation of Adaptation to Successive Postural Perturbations in Patients with Multiple Sclerosis

Hidden Markov Model and multifractal method-based predictive quantization complexity models vis-á-vis the differential prognosis and differentiation of Multiple Sclerosis’ subgroups

Investigating the Side Effects of Treatments Among Different Age and Gender Groups of Multiple Sclerosis Patients (P2-6.015)

Real World Ocrelizumab Experience of a Tertiary Center in Turkey (4528)

The Role of C3 and C4 Complement Levels in the Differential Diagnosis of Central Nervous System Demyelinating Diseases (P14-3.016)

Faible activité de la maladie après un traitement de 4 ans par ocrelizumab (OCR) chez des patients naïfs de traitement atteints de sclérose en plaques récurrente-rémittente (SEP-RR) à un stade précoce ; données de l’étude de phase IIIb ensemble

Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-naive Patients with High-activity, Early-stage Relapsing-remitting Multiple Sclerosis in the ENSEMBLE Study (P10-6.007)

Faible activité de la maladie chez des patients naïfs de traitement, atteints de sclérose en plaques récurrente-rémittente (SEP-RR) précoce, ayant reçu ocrélizumab (OCR) pendant 2 ans dans l’étude de phase IIIb ENSEMBLE

Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study (S46.004)

Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study (P7-3.003)

Investigation of Novel Variants in Familial Multiple Sclerosis Through Family-based Association Tests and Segregation Analyses (S17.007)

An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-β1 and fingolimod therapy

Erratum: Evaluating Treatment Decision for Multiple Sclerosis: Real Life and Patient Experiences

Multi-center, Randomized, Double-blinded Assessment of TERIFLUNOMIDE (Aubagio®) in Extending the Time to the First Attack in Radiologically Isolated Syndrome: Baseline Characteristics of the TERIS Study. (P5-4.011)

Evaluating Treatment Decision for Multiple Sclerosis: Real Life and Patient Experiences

Corrigendum to Myelin Oligodendrocyte Glycoprotein Antibody Associated Central Nervous System Demyelinating Disease: A Tertiary Center Experience From Turkey [Multiple Sclerosis and Related Disorders 44 (2020) 102376]

Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course

Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course

Corrigendum to "Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment" Multiple Sclerosis and Related Disorders, Volume 79, November 2023, 104949

Let’s raise the awareness of MS specialists concerning the frequency and impact of RLS in MS and consequently the life quality of patients with MS: Striking results of the ‘RELOMS-T’ Study (P1.424)

Optic Neuritis Presenting With Altitudinal Visual Field Defect in a Neuromyelitis Optica Patient

Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107)

Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis (2901)

Association of Latitude and Exposure to Ultraviolet B Radiation with Severity of Multiple Sclerosis (2554)

Aktive Filter

Suchergebnisse filtern